Transforming growth factor-β pathway activity in glioblastoma

Oncotarget

Volumn 6, Issue 8, 2015, Pages 5963-5977

  Frei, Karl ^a   Gramatzki, Dorothee ^b   Tritschler, Isabel ^b   Schroeder, Judith Johanna ^b   Espinoza, Larisa ^a   Rushing, Elisabeth Jane ^a   Weller, Michael ^b,c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Biomarker; Glioblastoma; PAI 1; PDGF B; TGF

Indexed keywords

ANTINEOPLASTIC AGENT; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR B; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BRAIN SURGERY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL PROLIFERATION; CHILD; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; TREATMENT OUTCOME; BRAIN TUMOR; CELL CULTURE; GENETICS; INFANT; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; PRESCHOOL CHILD; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; FEMALE; GLIOBLASTOMA; HUMANS; INFANT; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHOSPHORYLATION; TRANSFORMING GROWTH FACTOR BETA; YOUNG ADULT;

EID: 84925596863     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3467     Document Type: Article

References (24)

1. Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, Chinot O, Ram Z, Reifenberger G, Soffietti R, Wick W and European Association for Neuro-Oncology Task Force on Malignant G. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. The Lancet Oncology. 2014; 15(9):e395-403.
2. Cheng L, Huang Z, Zhou W, Wu Q, Donnola S, Liu JK, Fang X, Sloan AE, Mao Y, Lathia JD, Min W, McLendon RE, Rich JN and Bao S. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell. 2013; 153(1):139-152.
3. Seoane J. Escaping from the TGFbeta anti-proliferative control. Carcinogenesis. 2006; 27(11):2148-2156.
4. Shi Y and Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003; 113(6):685-700.
5. Massague J, Seoane J and Wotton D. Smad transcription factors. Genes & development. 2005; 19(23):2783-2810.
6. Bruna A, Darken RS, Rojo F, Ocana A, Penuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J and Seoane J. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer cell. 2007; 11(2):147-160.
7. Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C, Karlsson S and ten Dijke P. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Molecular cell. 2003; 12(4):817-828.
8. Ikushima H, Komuro A, Isogaya K, Shinozaki M, Hellman U, Miyazawa K and Miyazono K. An Id-like molecule, HHM, is a synexpression group-restricted regulator of TGF-beta signalling. The EMBO journal. 2008; 27(22):2955-2965.
9. Lamouille S, Connolly E, Smyth JW, Akhurst RJ and Derynck R. TGF-beta-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. Journal of cell science. 2012; 125(Pt 5):1259-1273.
10. Derynck R and Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003; 425(6958):577-584.
11. Eichhorn PJ, Rodon L, Gonzalez-Junca A, Dirac A, Gili M, Martinez-Saez E, Aura C, Barba I, Peg V, Prat A, Cuartas I, Jimenez J, Garcia-Dorado D, Sahuquillo J, Bernards R, Baselga J, et al. USP15 stabilizes TGF-beta receptor I and promotes oncogenesis through the activation of TGF-beta signaling in glioblastoma. Nature medicine. 2012; 18(3):429-435.
12. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455(7216):1061-1068.
13. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell. 2010; 17(1):98-110.
14. Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A, Balasubramaniam A, Nair S, Oliushine V, Parfenov V, Poverennova I, Zaaroor M, Jachimczak P, Ludwig S, Schmaus S, Heinrichs H, et al. Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro-oncology. 2011; 13(1):132-142.
15. Wick W and Weller M. Trabedersen to target transforming growth factor-beta: when the journey is not the reward, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142). Neuro-oncology. 2011; 13(5):559-560; author reply 561-552.
16. Azaro A, Baselga J, Sepúlveda JM, Seoane J, Ahnert JR, Brana I and al. e. The oral transforming growth factor-beta (TGF-β) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: the first human dose study. J Clin Oncol 2012; 30 (suppl; abstr 2042).
17. Suarez C, Rodon J, Desjardin A, Forsyth P, I G, Cleverly A and al e. Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF-β) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with chemoradiotherapy in newly diagnosed malignant gliomas. J Clin Oncol. 31 (suppl; abstr 2039).
18. Miyazawa K, Shinozaki M, Hara T, Furuya T and Miyazono K. Two major Smad pathways in TGF-beta superfamily signalling. Genes to cells: devoted to molecular & cellular mechanisms. 2002; 7(12):1191-1204.
19. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, Brem H, Olivi A, Dimeco F and Vescovi AL. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature. 2006; 444(7120):761-765.
20. Seoane J. Gremlins sabotage the mechanisms of cancer stem cell differentiation. Cancer cell. 2014; 25(6):716-717.
21. Fang KM, Yang CS, Lin TC, Chan TC and Tzeng SF. Induced interleukin-33 expression enhances the tumorigenic activity of rat glioma cells. Neuro-oncology. 2014; 16(4):552-566.
22. Louis DN, Ohgaki H, Wiestler B and Cavenee WK. WHO Classification of Tumours of the Central Nervous System. IARC Press, Lyon 2007.
23. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic acids research. 2001; 29(9):e45.
24. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C and Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer discovery. 2012; 2(5):401-404.